BCM
ALXN

BBT Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

BBT Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-30,000
Closed -$4.56M – 290
2014
Q1 		$4.56M Buy
+30,000
New +$4.77M 0.21% 124

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BBT Capital Management's ALXN Position: Q2 2014 in Review

BBT Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2014, closing a stake of 30,000 shares — an estimated $4.56M sold.

BBT Capital Management first reported a position in ALXN in Q1 2014 and held it in 1 quarter. The position peaked at $4.56M in Q1 2014. 521 funds tracked by Wall St. Rank hold ALXN as of Q2 2014.

  • BBT Capital Management reported no remaining Alexion Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • BBT Capital Management sold 30,000 Alexion Pharmaceuticals shares in Q2 2014, an estimated $4.56M.
  • BBT Capital Management first reported a position in Alexion Pharmaceuticals in Q1 2014 and held it in 1 quarter.
  • BBT Capital Management's Alexion Pharmaceuticals position peaked at $4.56M in Q1 2014.
  • 521 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2014.

Based on BBT Capital Management's 13F filing for Q2 2014, filed 8 Aug 2014.